Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help
Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#129 / 129 Total
PLRX - Pliant Therapeutics Inc - Stock Price Chart
TickerPLRX [NASD, RUT]
CompanyPliant Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap768.00MEPS (ttm)-2.86
P/E-EPS this Y-23.65%
Forward P/E-EPS next Y-9.70%
PEG-EPS past 5Y-22.68%
P/S3072.00EPS next 5Y-
P/B1.76EPS Q/Q-16.48%
Dividend-Sales Q/Q-100.00%
Insider Own11.49%Inst Own99.75%
Insider Trans-0.87%Inst Trans36.07%
Short Float14.13%EarningsMay 06/a
Analyst Recom1.00Target Price41.08
Avg Volume380.62K52W Range11.21 - 24.74
May-21-24 06:50PM Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference (GlobeNewswire)
May-14-24 11:28AM Pliant Therapeutics Reports Positive Topline Data in Idiopathic Pulmonary Fibrosis Trial (MT Newswires)
07:30AM Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis (GlobeNewswire)
May-07-24 08:35AM Oppenheimer Adjusts Price Target on Pliant Therapeutics to $48 From $47, Maintains Outperform Rating (MT Newswires)
08:00AM Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress (GlobeNewswire)
06:59AM RBC Cuts Price Target on Pliant Therapeutics to $45 From $54, Keeps Outperform, Speculative Risk (MT Newswires)
May-06-24 09:55PM PLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
04:05PM Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-01-24 08:00AM Pliant Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire) +7.11%
Apr-02-24 08:00AM Pliant Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. The company was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cummings Keith LamontChief Financial OfficerMay 02 '24Option Exercise2.0821,00043,680271,713May 06 06:02 AM
Coulie BernardPresident and CEOJan 17 '24Sale17.2325,721443,173316,382Jan 19 05:19 PM
Lefebvre EricChief Medical OfficerJan 17 '24Sale17.2310,295177,383156,920Jan 19 05:18 PM
Hull HansChief Business OfficerJan 17 '24Sale17.239,786168,613185,069Jan 19 05:19 PM
Cummings Keith LamontChief Financial OfficerJan 17 '24Sale17.239,781168,527194,605Jan 19 05:19 PM
1⋯8910111213
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.